Cystinuria

Cystinuria is an inherited metabolic disorder characterized by defective renal tubular reabsorption of cystine and other dibasic amino acids (ornithine, lysine, arginine), leading to excessive urinary excretion of cystine. Due to its poor solubility at physiological urine pH, cystine precipitates to form hexagonal crystals and calculi in the urinary tract, particularly in the bladder and urethra. The disease manifests clinically as urolithiasis, often with recurrent episodes of urethral obstruction, hematuria, and dysuria. Cystinuria is recognized in both dogs and cats, with a higher prevalence in certain breeds, and is classified into subtypes based on the specific genetic mutation and transporter defect. The condition is managed through medical dissolution, dietary modification, and surgical or interventional removal of calculi, with long-term strategies aimed at preventing recurrence.

Cystinuria is primarily a genetic disorder caused by mutations in genes encoding renal tubular amino acid transporters. In dogs, mutations in the SLC3A1 gene (encoding the heavy subunit rBAT) and SLC7A9 gene (encoding the light subunit b0,+AT) have been identified. These subunits form the heteromeric amino acid transporter responsible for reabsorption of cystine and dibasic amino acids in the proximal tubule. Specific mutations vary by breed; for example, in Newfoundlands, a mutation in SLC3A1 is common, while in Labrador Retrievers, SLC7A9 mutations are implicated. In cats, cystinuria is less common but has been reported, with some cases linked to SLC3A1 mutations. The disorder is inherited in an autosomal recessive manner in most breeds, but some forms may exhibit autosomal dominant inheritance with incomplete penetrance. The defective transporter leads to reduced reabsorption of cystine, ornithine, lysine, and arginine, resulting in hyperexcretion of these amino acids in urine. Cystine, being the least soluble, precipitates under acidic to neutral pH, forming crystals and calculi. Secondary causes of cystinuria are rare but may include Fanconi syndrome or other proximal tubular dysfunction, though the primary form is genetic.

Cystinuria is a significant cause of urolithiasis in dogs, accounting for approximately 1-3% of all canine uroliths, but with breed-specific prevalence much higher. Breeds with a known predisposition include the Newfoundland, Labrador Retriever, Golden Retriever, Australian Cattle Dog, Dachshund, Basset Hound, English Bulldog, Scottish Deerhound, and Mastiff. In Newfoundlands, the prevalence of cystinuria is estimated to be as high as 10-20% in some populations. The condition is less common in cats, with a few reported cases in breeds such as the Siamese and domestic shorthairs, but overall prevalence is low. Age of onset is typically in young to middle-aged adults, with most dogs presenting between 1 and 5 years of age, though some may be older. Sex predilection is notable: male dogs are more frequently affected clinically due to their longer, narrower urethra, which predisposes to urethral obstruction, whereas females may have asymptomatic cystinuria or pass calculi more easily. Geographic distribution is worldwide, but breed popularity influences regional prevalence. No clear seasonality is reported, but dehydration and concentrated urine may increase risk of stone formation.

The pathophysiology of cystinuria centers on the defective transport of cystine in the proximal renal tubule. Normally, cystine is filtered by the glomerulus and then reabsorbed via the b0,+AT transporter system in the S1 and S2 segments of the proximal tubule. In cystinuria, this transporter is dysfunctional due to genetic mutations, leading to decreased reabsorption and increased urinary excretion of cystine. Cystine is relatively insoluble in urine, with solubility dependent on pH and concentration. At typical urine pH (5.5-7.0), cystine solubility is limited, and when urinary cystine concentration exceeds approximately 300 mg/L, precipitation occurs. Cystine crystals form hexagonal plates that can aggregate to form calculi. These calculi are often multiple, smooth, and radiopaque due to sulfur content, though they may be less radiodense than calcium-containing stones. The presence of calculi in the urinary tract leads to mechanical irritation of the urothelium, causing hematuria, dysuria, and inflammation. Urethral obstruction is a common and life-threatening complication, particularly in males, leading to post-renal azotemia, electrolyte imbalances (hyperkalemia, hyperphosphatemia), and potentially bladder rupture. Chronic inflammation and obstruction can predispose to secondary bacterial urinary tract infections, further complicating the clinical picture. The defect also affects intestinal transport of cystine, but this does not appear to have significant clinical consequences.

Predisposing factors for cystinuria include genetic susceptibility, breed, sex, age, and environmental factors. Genetic mutations in SLC3A1 and SLC7A9 are the primary intrinsic factors, with certain breeds having a high prevalence of these mutations. Male sex is a significant risk factor for clinical disease due to anatomical differences in the urethra, making obstruction more likely. Age is a factor, with most cases presenting in young adulthood, but recurrence can occur throughout life. Environmental and management factors include low water intake, leading to concentrated urine and increased cystine concentration, which promotes crystallization. Urine pH is also important; acidic urine (pH < 7.0) decreases cystine solubility, while alkaline urine increases it. Dietary factors, such as high protein intake, can increase cystine production and excretion, although the effect is modest. Dehydration, whether from inadequate water consumption or excessive fluid loss, increases urine specific gravity and cystine concentration. Concurrent urinary tract infections can alter urine pH and promote stone formation. Additionally, stress and infrequent urination may contribute to urinary stasis, allowing crystals to aggregate.

Clinical signs of cystinuria are primarily related to urolithiasis and urinary tract obstruction. In peracute cases, especially with urethral obstruction, signs include anuria, stranguria, dysuria, hematuria, and abdominal distension. Affected animals may show signs of systemic illness such as vomiting, lethargy, anorexia, and dehydration due to post-renal azotemia. Acute obstruction can lead to hyperkalemia, which may cause bradycardia and cardiac arrhythmias, and if untreated, can be fatal. In subacute and chronic cases, signs may be more subtle, including intermittent hematuria, pollakiuria, and straining to urinate. Owners may notice blood in the urine or frequent attempts to urinate with small volumes. In some cases, cystine calculi may be asymptomatic and discovered incidentally on imaging. Chronic cystinuria can lead to recurrent urinary tract infections, which may cause pyuria and fever. In female dogs, calculi may pass more easily, but they can still cause irritation and hematuria. Physical examination may reveal a painful, distended bladder in cases of obstruction, and palpation may sometimes detect calculi in the bladder. In chronic cases, thickening of the bladder wall may be palpable. Systemic signs of uremia, such as oral ulceration, halitosis, and weakness, may be present in advanced obstruction.

Differential diagnoses for cystinuria include other causes of urolithiasis and lower urinary tract disease. Key differentials are: 1) Struvite urolithiasis: Often associated with urease-producing bacterial infections (e.g., Staphylococcus, Proteus), urine pH is typically alkaline, and crystals are coffin-lid shaped. Radiographically, struvite stones are radiopaque. 2) Calcium oxalate urolithiasis: Common in certain breeds (e.g., Miniature Schnauzer, Bichon Frise), urine pH is often acidic, and stones are radiopaque and spiculated. Hypercalciuria and hyperoxaluria may be present. 3) Urate urolithiasis: Seen in Dalmatians and dogs with portosystemic shunts, urate stones are radiolucent, and urine pH is acidic. Hyperuricemia and hyperuricosuria are characteristic. 4) Silicate urolithiasis: Associated with ingestion of silicate-containing materials (e.g., soil, plants), stones are radiopaque and may be jackstone-shaped. 5) Xanthine urolithiasis: Rare, often due to allopurinol therapy or genetic xanthine oxidase deficiency, stones are radiolucent. 6) Bacterial cystitis: Can cause hematuria and dysuria, but urinalysis shows pyuria and bacteriuria, and culture is positive. 7) Neoplasia of the urinary bladder (e.g., transitional cell carcinoma): May cause hematuria and obstruction, but imaging shows a mass, and cytology/histopathology is diagnostic. 8) Idiopathic feline lower urinary tract disease (FLUTD): In cats, can cause similar signs, but cystine stones are rare. 9) Urethral plugs: Often composed of matrix and struvite crystals, causing obstruction, but plugs are usually soft and may be expressed. 10) Trauma to the urinary tract: Can cause hematuria and obstruction, but history and imaging may reveal injury. Definitive diagnosis of cystinuria relies on identification of cystine crystals in urine sediment, positive cyanide-nitroprusside test, and quantitative amino acid analysis.

The diagnostic approach to cystinuria begins with a thorough history and physical examination, with particular attention to breed, age, sex, and clinical signs. If urolithiasis is suspected, initial diagnostic imaging is warranted. Abdominal radiography is often the first step; cystine stones are radiopaque but may be less dense than calcium-containing stones, so they may be faintly visible or missed if small. Ultrasonography is more sensitive for detecting bladder and urethral calculi, and can also assess for hydronephrosis or hydroureter in cases of obstruction. If urethral obstruction is present, emergency stabilization is required before further diagnostics. Once the patient is stable, a urinalysis should be performed, including urine pH, specific gravity, and sediment examination. The presence of hexagonal crystals is highly suggestive of cystinuria, but not definitive. A cyanide-nitroprusside test on urine can qualitatively detect cystine; a positive result is indicated by a red-purple color. For quantitative confirmation, urine amino acid analysis using high-performance liquid chromatography (HPLC) or ion-exchange chromatography can measure cystine concentration. Genetic testing for known mutations (e.g., SLC3A1, SLC7A9) is available for certain breeds and can confirm the diagnosis and guide breeding decisions. If calculi are present, analysis of retrieved stones (via voiding, surgery, or lithotripsy) provides definitive identification. In cases of obstruction, a complete blood count, serum biochemistry, and blood gas analysis are essential to assess renal function and electrolyte imbalances. Imaging of the upper urinary tract (ultrasound or CT) may be indicated to rule out nephroliths or ureteral calculi. A stepwise algorithm would be: 1) History and physical exam; 2) Emergency stabilization if obstruction; 3) Imaging (radiography, ultrasound); 4) Urinalysis with sediment exam; 5) Cyanide-nitroprusside test; 6) Quantitative urine amino acid analysis; 7) Genetic testing if indicated; 8) Stone analysis if available; 9) Baseline bloodwork to assess renal function and electrolytes.

Laboratory findings in cystinuria are primarily related to the urinary tract and secondary complications. Complete blood count (CBC) may be normal in uncomplicated cases, but may show neutrophilia with a left shift if there is a secondary bacterial infection or inflammation. In cases of urethral obstruction, hemoconcentration may be present due to dehydration, and stress leukogram may be seen. Serum biochemistry may reveal azotemia (elevated BUN and creatinine) in cases of post-renal obstruction, with elevations in phosphorus and potassium. Hyperkalemia is a critical finding and can cause cardiac arrhythmias. Metabolic acidosis may be present due to impaired excretion of acids. In chronic cases, renal function may be compromised, leading to persistent azotemia and electrolyte imbalances. Urinalysis is key: urine specific gravity is often high (>1.030) due to concentrated urine, unless renal failure is present. Urine pH is typically acidic to neutral (5.5-7.0). Sediment examination may show hexagonal cystine crystals, which are pathognomonic. Hematuria and pyuria may be present due to urolithiasis or infection. Proteinuria may be mild. Urine culture should be performed if infection is suspected. The cyanide-nitroprusside test is a qualitative screening test for cystine; a positive result is indicated by a red-purple color change. Quantitative urine amino acid analysis will show elevated cystine, ornithine, lysine, and arginine. In dogs, normal urinary cystine excretion is less than 100 mg/g creatinine, while affected dogs may excrete >300 mg/g creatinine. Blood gas analysis may show metabolic acidosis in obstructed patients. Additional biomarkers such as SDMA may be elevated in cases of reduced renal function.

Imaging plays a crucial role in the diagnosis and management of cystinuria. Abdominal radiography is often the first imaging modality. Cystine calculi are radiopaque due to their sulfur content, but their radiopacity is less than that of calcium oxalate or struvite stones. They may appear as smooth, round to oval, and often multiple stones in the bladder or urethra. However, small stones may be missed on radiographs. Ultrasonography is more sensitive for detecting bladder and urethral calculi, especially small ones. On ultrasound, cystine stones appear as hyperechoic foci with distal acoustic shadowing. Ultrasound can also assess bladder wall thickness, presence of masses, and hydronephrosis or hydroureter in cases of obstruction. In male dogs, urethral calculi may be identified via contrast urethrography or retrograde urohydropropulsion. Computed tomography (CT) is the most sensitive imaging modality for detecting uroliths, including cystine stones, and can provide detailed information on stone size, number, and location. CT is particularly useful for planning surgical or interventional procedures. Intravenous pyelography or CT urography may be used to assess the upper urinary tract for nephroliths or ureteral stones. In cases of urethral obstruction, a urinary catheter may be passed to relieve the obstruction, and contrast studies can delineate the location of calculi. Imaging is also used for follow-up to monitor for recurrence or dissolution of stones.

Cytology and histopathology are not typically required for the diagnosis of cystinuria, but they may be useful in certain situations. Fine needle aspiration (FNA) of a bladder mass or lesion may be performed if neoplasia is suspected, but cystine stones are not amenable to FNA. Urine cytology may show red blood cells, white blood cells, and crystals, but is not diagnostic for cystinuria. Histopathological examination of bladder tissue may be performed if there is chronic inflammation or suspected neoplasia. In cases of cystine urolithiasis, the stones themselves can be analyzed by crystallography or infrared spectroscopy, which is the gold standard for stone composition. Histopathology of the kidney may be performed in cases of chronic renal disease, but is not specific for cystinuria. In research settings, renal biopsy may show tubular damage, but this is not clinically indicated. Overall, cytology and histopathology are of limited value in cystinuria, and diagnosis relies on urinalysis, stone analysis, and genetic testing.

Treatment of cystinuria involves emergency management of urethral obstruction, medical dissolution of existing stones, and long-term prevention of recurrence. In cases of urethral obstruction, immediate stabilization is required. This includes fluid therapy to correct dehydration and electrolyte imbalances, particularly hyperkalemia. Hyperkalemia can be managed with intravenous fluids, calcium gluconate (0.5-1.0 mL/kg of 10% solution IV over 10-20 minutes) for cardioprotection, insulin and dextrose (regular insulin 0.1-0.2 U/kg IV followed by dextrose 2 g/U insulin), and sodium bicarbonate (1-2 mEq/kg IV) if severe acidosis. Relief of obstruction is achieved by urethral catheterization, retrograde urohydropropulsion, or cystocentesis to decompress the bladder. Once the patient is stable, definitive management of uroliths can be planned. Medical dissolution of cystine stones is possible with dietary modification and urinary alkalinization. A low-protein, low-methionine diet is recommended to reduce cystine production. Increasing water intake to dilute urine is essential. Urinary alkalinization is achieved with potassium citrate (initial dose 50-75 mg/kg PO q12h, adjusted to maintain urine pH between 7.0 and 7.5) or sodium bicarbonate (10-20 mg/kg PO q8-12h). The goal is to increase cystine solubility. In some cases, tiopronin (2-mercaptopropionylglycine) may be used to reduce cystine excretion by forming a more soluble disulfide complex. Tiopronin is given at a dose of 10-15 mg/kg PO q12h, but it is not widely available and may have side effects. If medical dissolution is not successful or if stones are causing obstruction, surgical removal (cystotomy) or minimally invasive techniques such as laser lithotripsy or voiding urohydropropulsion may be necessary. In cases of recurrent obstruction, urethrostomy may be considered. Long-term management includes continued dietary therapy, alkalinization, and regular monitoring. Antibiotics are indicated if a urinary tract infection is present. Analgesics such as opioids or NSAIDs may be used for pain management, but caution is needed with NSAIDs in patients with renal compromise.

The prognosis for cystinuria is generally good with appropriate management, but the condition is chronic and requires lifelong therapy. Short-term prognosis is excellent for uncomplicated cases, especially if stones are removed and medical therapy is initiated. However, recurrence is common if dietary and alkalinization measures are not strictly followed. In cases of urethral obstruction, the prognosis is guarded if treatment is delayed, as severe hyperkalemia and post-renal azotemia can be fatal. With prompt intervention, most animals recover. Long-term prognosis depends on the ability to maintain urine pH and dilution, and to prevent stone formation. Some dogs may develop chronic kidney disease due to recurrent obstruction or pyelonephritis, which can worsen the prognosis. Genetic testing can identify carriers and affected animals, allowing for informed breeding decisions. Overall, with diligent management, many affected dogs can live a normal lifespan, but owners must be committed to ongoing monitoring and therapy.

Follow-up for cystinuria is essential to monitor for recurrence and assess the effectiveness of therapy. Initially, after diagnosis or stone removal, re-evaluation should occur within 1-2 months. This includes a urinalysis to assess urine pH, specific gravity, and sediment for crystals. Urine pH should be measured regularly, ideally at home using pH strips, to ensure it remains in the target range (7.0-7.5). Imaging (ultrasound or radiography) should be repeated every 3-6 months to check for new stone formation. Serum biochemistry and renal function tests (BUN, creatinine, SDMA) should be monitored every 6-12 months, especially in patients with a history of obstruction. Urine culture should be performed if there are signs of infection. If the patient is on potassium citrate or other alkalinizing agents, dosages should be adjusted based on urine pH. If tiopronin is used, liver enzymes and blood counts should be monitored periodically. Owners should be educated on the importance of high water intake, and strategies to increase water consumption (e.g., wet food, water fountains) should be encouraged. Long-term follow-up is lifelong, with regular veterinary visits every 6-12 months for stable patients.

Pearls: 1) Cystine crystals are hexagonal and highly characteristic; their presence on urinalysis is almost diagnostic. 2) The cyanide-nitroprusside test is a quick, inexpensive screening test, but false positives can occur with other sulfur-containing compounds. 3) Cystine stones are radiopaque, but may be faint; ultrasound is more sensitive. 4) Medical dissolution is possible, but requires strict adherence to alkalinization and high water intake; success rates are high if urine pH is maintained above 7.0. 5) Genetic testing is available for many breeds and can guide breeding decisions. 6) In male dogs with recurrent obstruction, early surgical intervention (e.g., cystotomy) may be preferable to repeated catheterization. Pitfalls: 1) Failing to check urine pH regularly can lead to ineffective alkalinization and stone recurrence. 2) Using NSAIDs in patients with renal compromise can worsen kidney function. 3) Overlooking concurrent urinary tract infections, which can alter urine pH and complicate management. 4) Assuming that all radiopaque stones are calcium-based; cystine stones may be missed on radiographs. 5) Not considering cystinuria in breeds not typically associated with the disease, leading to misdiagnosis. 6) Inadequate fluid intake, which undermines all other therapeutic efforts.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for cystinuria: 1) Potassium citrate: Initial dose 50-75 mg/kg PO q12h, titrate to maintain urine pH 7.0-7.5. Available as tablets or powder. Side effects include gastrointestinal upset. Contraindicated in hyperkalemia. 2) Sodium bicarbonate: 10-20 mg/kg PO q8-12h, titrate to urine pH. Use with caution in patients with cardiac disease or edema. 3) Tiopronin (2-mercaptopropionylglycine): 10-15 mg/kg PO q12h, administered on an empty stomach. May cause vomiting, diarrhea, and proteinuria. Monitor liver enzymes and CBC. Not approved in all countries. 4) D-penicillamine: Alternative to tiopronin, but less commonly used due to side effects. Dose 10-15 mg/kg PO q12h, but may cause vomiting, anorexia, and immune-mediated reactions. 5) Antibiotics: If urinary tract infection is present, choose based on culture and sensitivity. Common choices include amoxicillin (11-22 mg/kg PO q8-12h), amoxicillin-clavulanate (13.75-25 mg/kg PO q8-12h), or fluoroquinolones (e.g., enrofloxacin 5-10 mg/kg PO q24h). Adjust for renal function. 6) Analgesics: For pain associated with urolithiasis or surgery, opioids such as buprenorphine (0.01-0.03 mg/kg IV/IM q8-12h) or tramadol (2-5 mg/kg PO q8-12h) may be used. NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h) can be used if renal function is normal, but avoid in dehydrated or azotemic patients. 7) Fluid therapy: For obstruction, IV fluids (e.g., Lactated Ringer's solution) at rates to correct dehydration and promote diuresis. 8) Dietary management: Prescription diets low in protein and methionine, such as Hill's Prescription Diet u/d or Royal Canin Urinary SO, are recommended. These diets also promote urine alkalinization and increased water intake. 9) In emergency hyperkalemia: Calcium gluconate 10% (0.5-1.0 mL/kg IV over 10-20 min), regular insulin (0.1-0.2 U/kg IV) followed by dextrose (2 g/U insulin), and sodium bicarbonate (1-2 mEq/kg IV) if acidotic.

Evidence-based literature on cystinuria in veterinary medicine includes several key studies and consensus guidelines. A landmark study by Henthorn et al. (2000) identified mutations in the SLC3A1 gene in Newfoundlands with cystinuria, establishing the genetic basis. Subsequent studies have identified SLC7A9 mutations in other breeds. A study by Osborne et al. (1999) evaluated medical dissolution of cystine uroliths in dogs using dietary modification and urinary alkalinization, reporting success rates of over 80% when urine pH was maintained above 7.0. Another study by Bartges et al. (2004) compared the efficacy of tiopronin and D-penicillamine in reducing cystine excretion, finding tiopronin to be more effective and better tolerated. The ACVIM consensus statement on urolithiasis (2016) provides guidelines for diagnosis and management, emphasizing the importance of stone analysis and genetic testing. A study by Lulich et al. (2016) evaluated the use of laser lithotripsy for cystine stones, showing it to be a safe and effective minimally invasive option. Regarding dietary management, a study by Stevenson et al. (2003) demonstrated that a low-protein diet significantly reduced cystine excretion in affected dogs. Overall, the literature supports a multimodal approach combining dietary therapy, alkalinization, and, when necessary, surgical or interventional removal, with regular monitoring to prevent recurrence.